Long-term suboxone treatment and its benefit on long-term remission for opiate dependence

African Journal of Psychiatry (South Africa)

Volumn 17, Issue 6, 2014, Pages

  Shah, Anish S ^a   Young, James ^b   Vieira, Karen ^a  

^a Napa State Hospital ^*  (United States)

^b Napa State Hospital   (United States)

Author keywords

Drug replacement therapy; Opiate dependence; Opiates; Opioid dependence; Opioid detoxification; Suboxone treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; CLONIDINE; METHADONE; NALTREXONE;

ABSTINENCE; ANXIETY; CLINICAL TRIAL (TOPIC); DETOXIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LONG TERM CARE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 84928142612     PISSN: 19948220     EISSN: None     Source Type: Journal    
DOI: 10.4172/Psychiatry.1000174     Document Type: Review

References (31)

1. Fishbain DA, Cole B, Lewis J (2008) What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 9: 444-459.
2. Turk DC, Swanson KS, Gatchel RJ (2008) Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 24: 497-508.
3. Boscarino JA, Rukstalis M, Hoffman SN. (2010) Risk factors for drug dependence among out-patients on opioid therapy in a large US healthcare system. Addiction 105: 1776-1782.
4. Ives TJ, Chelminski PR, Hammett-Stabler CA (2006) Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 6: 46-56.
5. Liebschutz JM, Saitz R, Weiss RD, et al. (2010) Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. The Journal of Pain 8: 1047-1055.
6. Wasan AD, Butler SF, Budman SH (2007) Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 8: 307-315.
7. Davis WR, Johnson BD (2008) Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend 92: 267-276.
8. Abuse, National Institute on Drug Abuse (2012) Principles of drug addiction treatment: A research-based guide. Bethesda, MD: National Institutes of Health.
9. Camí J, Farre M (2003) Mechanisms of disease: Drug addiction. N Engl J Med 349: 975-986.
10. Kosten TR, George TP (2002) The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 1: 13-20.
11. Ling W, Jacobs P, Hillhouse M (2010) From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. J Substance Abuse Treat 38: S53-S60.
12. Polomeni P, Schwan R (2014) Management of opioid addiction with buprenorphine: French history and current management. Int J Gen Med 7: 143-148.
13. Walsh SL, Eissenberg T (2003) The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 70: S13-S27.
14. Pirnay S, Borron SW, Giudicelli CP (2004) A critical review of the causes of death among post-mortem toxicological investigations: Analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99: 978-988.
15. Polsky D, Glick HA, Woody GE (2010) Cost-effectiveness of Extended Buprenorphine-Naloxone Treatment for Opioid-Dependent Youth: Data from a Randomized Trial. Addiction 105: 1616-1624.
16. Sittambalam CD, Vij R, Ferguson RP (2014) Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction? J Community Hosp Intern Med Perspect 4: 22902.
17. Yokell MA, Zaller ND, Rich JD (2012) Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose. J Opioid Manag 8: 63-66.
18. Cascade EF, Randall P, Stine S. (2007) Trend watch: Prescribing for buprenorphine in the treatment of opioid addiction. Psychiatry 4: 15-16.
19. Fudala PJ, Bridge TP, Herbert S (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxon. N Engl J Med 349 949-958.
20. Digiusto E, Shakeshaft A, Ritter A, NEPOD Research Group (2004) Serious adverseevents in the Australian National Evaluation of Pahrmacotherapies for Opioid Dependence (NEPOD). Addiction 99: 450-460.
21. Bell JR, Butler B, Lawrance A (2009) Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 104: 73-77.
22. Blum K, Chen TJ, Bailey J (2011) Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? Mol Neurobiol 44: 250-268.
23. Ziedonis DM, Amass L, Steinberg M (2009) Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend 99: 28-36.
24. Ling W, Amass L, Shoptow M, et al. (2005) A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse's Clinical Trial Network. Addiction 100: 1090-1100.
25. Amass L, Ling W, Freese TE (2005) Bringing buprenorphine-naloxone detoxification to community treatment programs: The NIDA Clinical Trial Network field experience. Am J Addict 13: S42-S66.
26. Brigham GS, Amass L, Winhusen T (2007) Using buprenorphine shortterm taper to facilitate early treatment engagement. J Subst Abuse Treat 32: 349-356.
27. Collins ED, Horton T, Reinke K (2007) Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation. J Subst Abuse Treat 32: 167-175.
28. Katz EC, Schwartz RP, King S (2009) Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes. Am J Drug Alcohol Abuse 35: 63-67.
29. Ling W, Hillhouse M, Domier C (2009) Buprenorphine tapering schedule and illicit opioid use. Addiction 104: 256-265.
30. Woody GE, Poole SA, Subramaniam G (2008) Extended vs. short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA 300: 2003-2011.
31. Bilban M, Kastelic A, Zaletel-Kragelj L (2008) Ability to work and employability of patients in opioid substitution treatment programs in Slovenia. Croat Med J 49: 842-852.